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medical records of all patients who underwent thyroid surgery. Of an initial group of 480 medical charts found, 199 cases were eligible and were used for the effectiveness analysis. There were 155 women (78%) with a median age of 47 years (range: 13 -82), and 44 males (22%) with a median age of 49 years (range: 20 -71).
Study design
This was a retrospective within-group comparison study based on a review of medical records, as identified from a single centre (the Long Island Jewish Medical Center). A single group of patients who underwent both FNAB and FSE was evaluated. The patients were not followed after the final surgical intervention was performed. All the patients were evaluable at the end of the study.
Analysis of effectiveness
All of the patients included in the initial sample were taken into account in the effectiveness study. The effectiveness analysis compared the diagnostic results obtained with FNAB and FSE. Indeterminate FNAB results were classified as indeterminate, follicular neoplasm (FN), Hurthle cell neoplasm (HCN) and indeterminate with papillary features (IPF). Diagnoses made by FSE were classified as benign, malignant, or deferred for final pathologic examination. Twenty-one patients with indeterminate FNAB results, but whose FNAB results were suggestive of papillary cancer, were considered separately. The findings of FNAB and FSE were confirmed through a final pathologic examination.
Effectiveness results
In the sub-group of 21 patients whose FNAB results were suggestive of papillary cancer, there were 20 cancers (95%). Malignancy was diagnosed by FSE in 14 (67%) patients, the diagnosis was deferred in 6 patients, and in one patient the results were interpreted as malignant (1 false positive result).
In the sample comprising the remaining 178 patients, there were 64 (36%) cases of cancer.
Of these 64 cases, the FNAB results were indeterminate for 30 patients, FN for 14 patients, HCN for 12 patients, and IPF for 8 patients.
Of the same group of 64 cases, FSE identified 30 cases of cancer (47%). Fifty-three per cent (16 out of 30) of these were classified by FNAB as indeterminate, 29% (4 out of 14) as FN, 25% (3 out of 12) as HCN, and 88% (7 out of 8) as IPF.
There was one false-positive result with FNAB, but no false-negative results were observed. Of the 121 FSE that were deferred, 42 (35%) were cancers. The likelihood of making an accurate diagnosis with FSE was related to FNAB category and the final pathological examination results. For each of the FNAB categories (indeterminate, FN, HCN and IPF) FSE identified, respectively: 60% (indeterminate), 27% (FN), 40% (HCN) and 88% (IPF) of patients with papillary cancer; 29% (indeterminate), 0 (FN), 17% (HCN) and 0 (IPF) of patients with Hurthle cell cancer; and 33% (indeterminate), 33% (FN), 0 (HCN) and 0 (IPF) of patients with follicular cancer Overall, in the overall sample of 178 patients, FSE detected 17% of cancers.
Clinical conclusions
The effectiveness evidence showed that, in patients whose FNAB results were suggestive of papillary cancer, FSE was not useful because FNAB detected almost 100% of the cancers. However, the routine use of FSE was effective in identifying cancer cases, and reduced the number of patients requiring a second surgical procedure.
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